Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

DUBLIN , April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25 th Annual Needham Healthcare Conference. Company management...

JAZZ : 186.96 (+0.01%)
Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains...

JAZZ : 186.96 (+0.01%)
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness

JAZZ : 186.96 (+0.01%)
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026

Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally...

JAZZ : 186.96 (+0.01%)
1 Value Stock to Research Further and 2 We Ignore

1 Value Stock to Research Further and 2 We Ignore

PUBM : 8.46 (+2.30%)
JAZZ : 186.96 (+0.01%)
G : 37.37 (-0.98%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

COLL : 32.74 (+1.33%)
JAZZ : 186.96 (+0.01%)
BDX : 155.00 (+0.32%)
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

JAZZ : 186.96 (+0.01%)
Jazz: Q4 Earnings Snapshot

Jazz: Q4 Earnings Snapshot

JAZZ : 186.96 (+0.01%)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

JAZZ : 186.96 (+0.01%)
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –

JAZZ : 186.96 (+0.01%)

Barchart Exclusives

Hedge Funds Are Betting Against Super Micro. Should You Go Against the Grain and Buy SMCI Stock Here?
As Super Micro Computer battles legal turmoil and rising bearish bets, should investors still consider buying SMCI stock now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.